Deals channel feed

Ge­nomics biotech un­der­goes a facelift, re­brand­ing from Clover to Char­ac­ter Bio­sciences

3 years ago
R&D

As­traZeneca picks up suite of new Covid-19 an­ti­bod­ies, shin­ing spot­light on Ox­ford-tied start­up

3 years ago
Coronavirus

Alde­vron and In­scrip­ta ink man­u­fac­tur­ing deal for CRISPR Type-V nu­cle­ase

3 years ago
R&D
Pharma

Sh­iono­gi backs F2G in de­vel­op­ing rare-dis­ease an­ti­fun­gal in Eu­rope and Asia

3 years ago

Ot­su­ka calls off multi­bil­lion-dol­lar, CKD li­cens­ing deal with Ake­bia in af­ter­math of CRL

3 years ago
FDA+

Treg space con­tin­ues to heat up as Ab­b­Vie puts up al­most $50M up­front to part­ner with lit­tle-known biotech

3 years ago

Or­p­hazyme agrees to sell it­self, and its 'pipeline-in-a-prod­uct,' to Kem­Pharm

3 years ago

Bris­tol My­ers Squibb strikes deal to sell NY site to South Ko­re­an con­glom­er­ate — but it's keep­ing qui­et on the de­tails

4 years ago
Pharma
Manufacturing

Re­gen­eron did­n't want to 'bid against it­self' in Check­mate deal as five glob­al phar­mas de­clined to coun­terof­fer

4 years ago
Pharma

Work­ing to right the ship, Bridge­Bio's Neil Ku­mar adds a $110M deal right on top of his cash haul from Bris­tol My­ers

4 years ago
Bioregnum

A week af­ter dis­clos­ing lay­offs, Bridge­Bio nets a $90M up­front can­cer R&D pact with Bris­tol My­ers

4 years ago
R&D
Pharma

Cul­li­nan On­col­o­gy goes full cir­cle, scor­ing $275M for shar­ing the load on EGFR in­hibitor with orig­i­nal de­vel­op­er

4 years ago

Pro­tein degra­da­tion field turns red hot as Bris­tol My­ers signs up for an­oth­er multi­bil­lion-dol­lar pact

4 years ago

Cap­ping a tur­bu­lent saga around Alzheimer's drug, Cor­texyme strikes a deal, brings in new man­age­ment and changes name in search of new life

4 years ago

As Sanofi prunes pipeline, ex-Alex­ion crew at Rally­bio picks up ane­mia drug

4 years ago
Pharma

Pfiz­er buys Bio­haven for $11.6B, go­ing all in on CGRP mi­graine drug port­fo­lio

4 years ago

Ex­clu­sive: No­vo Nordisk al­lies it­self with one of the buzzi­est groups in biotech, launch­ing a mul­ti-pronged at­tack at dis­cov­er­ing new drugs

4 years ago
R&D

J&J ends he­pati­tis B and HPV por­tions of Bavar­i­an Nordic col­lab

4 years ago
Pharma

A record num­ber of small biotechs are now trad­ing be­low cash. Is this the bot­tom yet?

4 years ago

Bio­gen taps dig­i­tal ther­a­peu­tics biotech for mu­sic-based ther­a­py to help peo­ple with MS im­prove their walk­ing

4 years ago

Il­lu­mi­na and Deer­field link arms to dri­ve 'ge­nomics-first' drug dis­cov­ery

4 years ago
Discovery

Big Phar­ma is rich. So much so, their cof­fers could buy more than 600 biotechs

4 years ago
Financing
Pharma

In­ter­cept sells ex-US rights to PBC drug as it gears up for a sec­ond-chance shot at NASH

4 years ago
Financing
Pharma

Jazz dou­bles down on sleep dis­or­ders, putting down $50M cash to pluck Sum­it­o­mo drug for the pipeline

4 years ago
First page Previous page 58596061626364 Next page Last page
A service from the Financial Times